CUDC-907

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
CUDC-907
Accession Number
DB11891
Type
Small Molecule
Groups
Investigational
Description

CUDC-907 has been used in trials studying the treatment of Lymphoma, Solid Tumors, BREAST CANCER, Multiple Myeloma, and NUT Midline Carcinoma, among others.

Structure
Thumb
3D
Similar Structures
Synonyms
Not Available
External IDs
CUDC907
Categories
UNII
3S9RX35S5X
CAS number
1339928-25-4
Weight
Average: 508.56
Monoisotopic: 508.164122459
Chemical Formula
C23H24N8O4S
InChI Key
JOWXJLIFIIOYMS-UHFFFAOYSA-N
InChI
InChI=1S/C23H24N8O4S/c1-30(23-25-11-15(12-26-23)22(32)29-33)13-16-9-17-19(36-16)21(31-5-7-35-8-6-31)28-20(27-17)14-3-4-18(34-2)24-10-14/h3-4,9-12,33H,5-8,13H2,1-2H3,(H,29,32)
IUPAC Name
N-hydroxy-2-({[2-(6-methoxypyridin-3-yl)-4-(morpholin-4-yl)thieno[3,2-d]pyrimidin-6-yl]methyl}(methyl)amino)pyrimidine-5-carboxamide
SMILES
COC1=CC=C(C=N1)C1=NC(N2CCOCC2)=C2SC(CN(C)C3=NC=C(C=N3)C(=O)NO)=CC2=N1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Unlock Additional Data
AbexinostatThe risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Abexinostat.
AcebutololThe risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Acebutolol.
AceprometazineThe risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Aceprometazine.
AcetyldigoxinThe risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Acetyldigoxin.
AcrivastineThe risk or severity of QTc prolongation can be increased when Acrivastine is combined with CUDC-907.
AdenosineThe risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Adenosine.
AjmalineThe risk or severity of QTc prolongation can be increased when Ajmaline is combined with CUDC-907.
AlfuzosinThe risk or severity of QTc prolongation can be increased when Alfuzosin is combined with CUDC-907.
AlimemazineThe risk or severity of QTc prolongation can be increased when Alimemazine is combined with CUDC-907.
AmantadineThe risk or severity of QTc prolongation can be increased when Amantadine is combined with CUDC-907.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
54575456
PubChem Substance
347828226
ChemSpider
29314960
BindingDB
50188961
ChEMBL
CHEMBL3622533
ZINC
ZINC000073488511
Wikipedia
Phosphoinositide_3-kinase_inhibitor

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentDiffuse Intrinsic Pontine Glioma (DIPG) / Recurrent Anaplastic Astrocytoma / Recurrent Glioblastoma / Recurrent Malignant Gliomas / Recurrent Medulloblastoma1
1CompletedTreatmentBreast Cancer / High-grade Serous Ovarian Cancer / NUT Midline Carcinoma (NMC) / Triple-Negative Breast Cancer (TNBC) / Tumors, Solid1
1RecruitingTreatmentDouble-expressor Lymphoma (DEL) / Double-hit Lymphoma (DHL) / High-grade B-cell Lymphoma (HGBL) / Malignant Lymphomas / Multiple Myeloma (MM) / Refractory Diffuse Large B-cell Lymphoma (DLBCL) / Refractory Lymphomas / Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) / Relapsed and/or Refractory Lymphoma / Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL) / Relapsed Lymphomas / Triple-hit Lymphoma (THL)1
1RecruitingTreatmentMalignant Lymphomas / Neoplasms, Brain / Neuroblastomas / Tumors, Solid1
2CompletedTreatmentRelapsed and/or Refractory Diffuse Large B-cell Lymphoma / Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations1
2TerminatedTreatmentDifferentiated Thyroid Cancer (DTC) / Neoplasms, Thyroid / Poorly Differentiated and Undifferentiated Thyroid Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0153 mg/mLALOGPS
logP2.59ALOGPS
logP2.78ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)9.24ChemAxon
pKa (Strongest Basic)3.36ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count11ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area138.72 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity145.82 m3·mol-1ChemAxon
Polarizability53.01 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as pyridinylpyrimidines. These are compounds containing a pyridinylpyrimidine skeleton, which consists of a pyridine linked (not fused) to a pyrimidine by a bond.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazines
Sub Class
Pyrimidines and pyrimidine derivatives
Direct Parent
Pyridinylpyrimidines
Alternative Parents
Thienopyrimidines / Pyrimidinecarboxamides / 2,3,5-trisubstituted thiophenes / Dialkylarylamines / Alkyl aryl ethers / Aminopyrimidines and derivatives / Pyridines and derivatives / Morpholines / Imidolactams / Heteroaromatic compounds
show 6 more
Substituents
Pyridinylpyrimidine / Thienopyrimidine / Pyrimidine-5-carboxylic acid or derivatives / Pyrimidinecarboxamide / Dialkylarylamine / 2,3,5-trisubstituted thiophene / Alkyl aryl ether / Aminopyrimidine / Morpholine / Oxazinane
show 18 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 14:57 / Updated on March 01, 2020 21:01

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates